NextCure and Collaborators Provide Data on Developing Targets to the American Society of … | News

BELTSVILLE, Maryland, December 13, 2021 (GLOBE NEWSWIRE) – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company engaged in the discovery and development of new, first-class immune drugs to treat cancer and other diseases related to the immune system, today announced new data in Oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia, and on a virtual platform. The data comes from preclinical research studies in collaboration with Emory University evaluating the role of Siglec-15 (S15) in acute B-cell lymphoblastic leukemia (ALL-B) and the potential to target S15 in childhood leukemia, and preclinical research studies conducted in collaboration with Vanderbilt University evaluating the impact of LAIR-1 expression on acute myeloid leukemia (AML) blasts and the use of LAIR-1 monoclonal antibodies in the treatment of AML.

“We explored with collaborators the potential of new treatments targeting Siglec-15 and LAIR-1 for hematological indications. This research led to the development of NC525, a monoclonal antibody against LAIR-1 with specific applications in AML and other hematologic malignancies, ”said Han Myint, MD, medical director of NextCure. “The data from both studies show encouraging signs that our treatment approaches may be beneficial for patients with multiple aggressive forms of leukemia. We continue to advance new research programs as well as our ongoing clinical evaluation of NC318, NC410 and NC762, in solid tumors, and remain motivated to identify new treatment solutions for patients who need them. “

Details of the presentations are below:

Siglec-15 is a novel immunomodulatory protein and a therapeutic target in acute lymphoblastic leukemia

Since S15 is widely expressed in hematologic malignancies and has been observed to suppress the T cell effector and memory population expansion on leukemic cells, it has potential as a target in the treatment of aggressive and refractory pediatric ALL. In addition, our collaborators discovered that a biomarker of interest, soluble S15 (sS15), circulates at higher levels in the plasma of pediatric patients with ALL-B compared to healthy donors. In this study, researchers eliminated S15 in a mouse model of immunocompetent and immunodeficient B-ALL cells. Highlights include:

The results suggest that S15 is a potent new immunosuppressive molecule that can be therapeutically targeted to activate T cells against leukemia cells. S15 has demonstrated its ability to promote immunosuppressive effects both at the bone marrow and systemic level. Knockout of S15 in a mouse model resulted in clearance of leukemia. in immunocompetent recipients and 100% survival in all recipients.

New LAIR-1 antibody selectively targets acute myeloid leukemia (AML) stem cells

Patients with AML who do not respond to standard therapy (SOC) face a lack of treatment options and the likelihood of relapse due to the persistence of chemotherapy-resistant leukemic stem cells (LSC). Since LSCs and AML blast cells are characterized by high expression of LAIR-1, a checkpoint receptor that delineates activation of immune cells, targeting LAIR-1 has the potential to promote immune responses in these patients. We have developed a LAIR-1 monoclonal antibody (mAb) to disrupt LAIR-1 mediated survival signaling. Highlights include:

It has been shown that mAb LAIR-1 preferentially targets and kills AML LSCs and LAIR-1 expressing blast cells. MAb exerts its anti-tumor activity through disruption of survival signals in leukemia cells and Fc-mediated effector functions. The use of mAb had minimal effect on healthy hematopoietic stem and progenitor cells (HSPC).

About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company engaged in the discovery and development of new, first-class immune drugs to treat cancer and other diseases related to the immune system. Through our exclusive FIND-IO ™ platform, we study various immune cells to discover and understand the targets and structural components of immune cells and their functional impact in disease in order to develop immunodrugs. Our initial goal is to bring hope and new treatments to patients who do not respond to current cancer therapies, to patients whose cancer progresses despite treatment, and to patients whose types of cancer are not being properly treated by them. therapies available.

Caution Regarding Forward-Looking Statements Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects”, “believes”, “intention”, “hope”, “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedical targets and the discovery and development of immunomedical drugs. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. These risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need for additional funding; risks associated with clinical development, including the fact that early clinical data may not be confirmed by subsequent clinical results; the risks that preclinical research will not be confirmed in clinical trials; risks associated with marketing authorization and marketing; and the unproven approach to product candidate discovery and development based on our FIND-IO platform. More detailed information on these and other factors that could affect the actual results of NextCure are described in the documents filed by NextCure with the Securities and Exchange Commission (the “SEC”), including the Form 10-K most. recent from NextCure and the subsequent Form 10-Q. You should not place undue reliance on forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Surveys Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 [email protected]

Copyright 2021 GlobeNewswire, Inc.

Previous Mondelēz Thailand's HR strategy is anchored around capacity, capabilities and culture
Next Cheryl Moore of Cañon City continues to receive accolades for her photography skills - Canon City Daily Record